27622027|t|CD169 identifies an activated CD8(+) T cell subset in regional lymph nodes that predicts favorable prognosis in colorectal cancer patients
27622027|a|CD169 was first identified on macrophages (Mϕ) and linked to antigen presentation. Here, we showed CD169 expression on some CD8(+) T lymphocytes in regional lymph nodes (LNs) and investigated the function and clinical relevance of CD169(+)CD8(+) T cells in tumor-draining LNs of colorectal cancer (CRC) patients. Fresh tumor-draining LN tissues from 39 randomly enrolled patients were assessed by flow cytometry for activation and differentiation of CD169(+)CD8(+) T cells and T cell-mediated killing of tumor cells. In total, 114 tumor-draining LN paraffin sections from CRC patients were analyzed by multiple-color immunofluorescence for CD169(+)CD8(+) T cell distribution and clinical values. The prognostic significance of CD169(+)CD8(+) T cells was evaluated by Kaplan-Meier analysis. A fraction of CD8(+) T cells in regional LNs, but not peripheral blood, tonsils, or tumors, expressed surface CD169. In situ detection of draining LNs revealed preferential localization of CD169(+)CD8(+) T cells to subcapsular sinus and interfollicular regions, closely associated with CD169(+) Mϕ. CD169(+)CD8(+) T cell ratios were significantly lower in peri-tumor LNs than distant-tumor LNs. CD169(+)CD8(+) T cells predominantly expressed activation markers (CD69, HLA-DR, PD-1) with slightly lower CD45RA and CD62L levels. They produced high granzyme B, perforin, TNF-α, and IFNγ levels, and promoted tumor-killing efficiency ex vitro. Moreover, CD169(+)CD8(+) T cells infiltrating tumor-draining LNs decreased with disease progression and were strongly associated with CRC patient survival. We identified novel activated / cytolytic CD169(+)CD8(+) T cells selectively present in regional LNs, potentially serving as a powerful prognostic factor and indicator for selecting patients for immunotherapy.
27622027	0	5	CD169	T116,T123	C1608815
27622027	6	16	identifies	T033	C0243095
27622027	20	29	activated	T025	C1515879
27622027	30	43	CD8(+) T cell	T025	C0242629
27622027	44	50	subset	T185	C0079720
27622027	54	74	regional lymph nodes	T023	C1179441
27622027	80	88	predicts	T078	C0681842
27622027	89	98	favorable	T080	C3640814
27622027	99	108	prognosis	T058	C0033325
27622027	112	129	colorectal cancer	T191	C1527249
27622027	130	138	patients	T101	C0030705
27622027	139	144	CD169	T116,T123	C1608815
27622027	169	180	macrophages	T025	C0024432
27622027	182	184	Mϕ	T025	C0024432
27622027	200	220	antigen presentation	T043	C0206431
27622027	238	254	CD169 expression	T045	C0017262
27622027	263	283	CD8(+) T lymphocytes	T025	C0242629
27622027	287	307	regional lymph nodes	T023	C1179441
27622027	309	312	LNs	T023	C1179441
27622027	318	330	investigated	T169	C1292732
27622027	335	343	function	T039	C0031843
27622027	348	366	clinical relevance	T033	C0243095
27622027	370	392	CD169(+)CD8(+) T cells	T025	C0039194
27622027	396	414	tumor-draining LNs	T023	C0024204
27622027	418	435	colorectal cancer	T191	C1527249
27622027	437	440	CRC	T191	C1527249
27622027	442	450	patients	T101	C0030705
27622027	452	483	Fresh tumor-draining LN tissues	T024	C0440747
27622027	492	500	randomly	T080	C0439605
27622027	501	518	enrolled patients	T033	C4316108
27622027	524	532	assessed	T052	C1516048
27622027	536	550	flow cytometry	T059	C0016263
27622027	555	565	activation	T025	C1440937
27622027	570	585	differentiation	T043	C0007589
27622027	589	611	CD169(+)CD8(+) T cells	T025	C0039194
27622027	616	654	T cell-mediated killing of tumor cells	T043	C1523368
27622027	670	687	tumor-draining LN	T023	C0024204
27622027	711	714	CRC	T191	C1527249
27622027	715	723	patients	T101	C0030705
27622027	741	774	multiple-color immunofluorescence	T059	C0016318
27622027	779	800	CD169(+)CD8(+) T cell	T025	C0039194
27622027	801	813	distribution	T169	C1704711
27622027	839	849	prognostic	T170	C0220901
27622027	850	862	significance	T080	C0205556
27622027	866	888	CD169(+)CD8(+) T cells	T025	C0039194
27622027	893	902	evaluated	T058	C0220825
27622027	906	927	Kaplan-Meier analysis	T081	C1720943
27622027	931	942	fraction of	T081	C1264633
27622027	943	957	CD8(+) T cells	T025	C0242629
27622027	961	973	regional LNs	T023	C1179441
27622027	983	999	peripheral blood	T031	C0229664
27622027	1001	1008	tonsils	T023	C0836921
27622027	1013	1019	tumors	T191	C0027651
27622027	1021	1044	expressed surface CD169	T116,T123	C1608815
27622027	1046	1053	In situ	T082	C0444498
27622027	1054	1063	detection	T061	C1511790
27622027	1067	1079	draining LNs	T023	C0024204
27622027	1080	1088	revealed	T080	C0443289
27622027	1102	1114	localization	T169	C0475264
27622027	1118	1140	CD169(+)CD8(+) T cells	T025	C0039194
27622027	1144	1161	subcapsular sinus	T024	C1518052
27622027	1166	1189	interfollicular regions	T029	C1512836
27622027	1199	1214	associated with	T080	C0332281
27622027	1215	1226	CD169(+) Mϕ	T025	C0024432
27622027	1228	1249	CD169(+)CD8(+) T cell	T025	C0039194
27622027	1250	1256	ratios	T081	C0456603
27622027	1285	1295	peri-tumor	T082	C1254362
27622027	1296	1299	LNs	T023	C0024204
27622027	1305	1318	distant-tumor	T082	C1254362
27622027	1319	1322	LNs	T023	C0024204
27622027	1324	1346	CD169(+)CD8(+) T cells	T025	C0039194
27622027	1347	1360	predominantly	T080	C0205556
27622027	1371	1389	activation markers	T201	C0005516
27622027	1391	1395	CD69	T116,T129	C0108800
27622027	1397	1403	HLA-DR	T116,T129	C0019764
27622027	1405	1409	PD-1	T116,T123	C0135710
27622027	1431	1437	CD45RA	T116,T129	C0108789
27622027	1442	1447	CD62L	T116,T129,T192	C0125090
27622027	1448	1454	levels	T080	C0441889
27622027	1470	1474	high	T080	C0205250
27622027	1475	1485	granzyme B	T116,T126	C0061878
27622027	1487	1495	perforin	T116,T123	C0070410
27622027	1497	1502	TNF-α	T116,T129	C1456820
27622027	1508	1512	IFNγ	T116,T121,T129	C3539881
27622027	1513	1519	levels	T080	C0441889
27622027	1534	1558	tumor-killing efficiency	T061	C1446301
27622027	1559	1567	ex vitro	T082	C1254362
27622027	1579	1601	CD169(+)CD8(+) T cells	T025	C0039194
27622027	1602	1614	infiltrating	T046	C0332448
27622027	1615	1633	tumor-draining LNs	T023	C0024204
27622027	1634	1643	decreased	T081	C0205216
27622027	1649	1668	disease progression	T046	C0242656
27622027	1687	1702	associated with	T080	C0332281
27622027	1703	1706	CRC	T191	C1527249
27622027	1707	1714	patient	T101	C0030705
27622027	1715	1723	survival	T052	C0038952
27622027	1728	1738	identified	T080	C0205396
27622027	1745	1754	activated	T025	C1440937
27622027	1757	1789	cytolytic CD169(+)CD8(+) T cells	T025	C0039195
27622027	1813	1825	regional LNs	T023	C1179441
27622027	1861	1878	prognostic factor	T201	C1514474
27622027	1883	1892	indicator	T169	C1522602
27622027	1897	1906	selecting	T052	C1707391
27622027	1907	1915	patients	T101	C0030705
27622027	1920	1933	immunotherapy	T061	C0021083